Clinical trials: Staphylococcus Infections
Atopic Dermatitis, Staphylococcus Aureus
Staphylococcal Toxins in Atopic Dermatitis and Eczema Herpeticum
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. Clinical studies have demonstrated a link between staphylococcal skin colonization and the pathogenesis of AD, but the implication of bacterial…
- Conditions
- Atopic Dermatitis, Staphylococcus Aureus, Bacterial Toxins, Immune Response
- Trial name
- STADEH (NCT04274348)
- Testing
- Skin biopsies and blood samples
- Where
- 2 sites in France
- Volunteers
- 41 people
- Sponsor
- Poitiers University Hospital
Healthy
Inflammation, Intracellular Invasion and Colonization of the Nasal Mucosa by Staphylococcus Aureus
An inflammatory state of the nasal cells (very close to keratinocytes) could favour the internalization of Staphylococcus aureus and thus constitute a persistent reservoir for the carriage of this bacterium.
- Trial name
- I3COSa (NCT04469348)
- Testing
- nasal swab
- Where
- France
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Skin Infections, Bacterial
GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection
This study will determine the safety, tolerability and efficacy of GSK1322322 verses Linezolid in subjects with Acute Bacterial Skin and Skin Structure Infection (ABSSSI).
- Trial name
- NCT01209078
- Testing
- GSK1322322, Linezolid
- Where
- 7 sites in United States
- Volunteers
- 84 people
- Sponsor
- GlaxoSmithKline
Autosomal-dominant Hyper-IgE Syndrome
Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome
Background: AD-HIES is a disease that weakens the immune system. It puts people at risk for infections, particularly Staph and Candida infections.
- Trial name
- NCT02996448
- Testing
- NDV-3A
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Bacteremia
Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
The intent of this study is to describe the safety and efficacy of daptomycin versus standard of care (SOC) in pediatric participants aged 1-17 years with bacteremia caused by Staphylococcus aureus (S. aureus).
- Trial name
- NCT01728376
- Testing
- Daptomycin, Comparator
- Volunteers
- 82 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Soft Tissue Infections, Necrotizing Fasciitis
Systems Medicine to Study Necrotizing Soft Tissue Infections (NSTIs).
This proposal focuses on highly lethal destructive tissue infections, i.e. necrotizing fasciitis and other necrotizing soft tissue infections (NSTIs), which are associated with high morbidity and mortality.
- Conditions
- Soft Tissue Infections, Necrotizing Fasciitis, Necrotizing Soft Tissue Infections
- Trial name
- INFECT (NCT01790698)
- Where
- 5 sites in Denmark, Norway and 1 more
- Volunteers
- 409 people
- Sponsor
- Karolinska Institutet
Staphylococcus Aureus
Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial
This study involves the use of investigational vaccines. A vaccine is a medicine that causes the body to make antibodies. Antibodies help destroy foreign substances that enter the body.
- Trial name
- NCT01011335
- Testing
- Monovalent rAT, Monovalent rLukS-PV, Bivalent rLukS-PV / rAT
- Where
- 2 sites in United States
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Pneumonia
Clinical Outcomes of Methicillin Resistant Staphylococcus Aureus (MRSA) Hospital-Based Pneumonia
The purpose of this non-interventional, retrospective study of existing data is to evaluate clinical outcomes related to Methicillin-resistant Staphylococcus aureus hospital based pneumonia by treatment and among subpopulations.
- Trial name
- NCT01819935
- Testing
- linezolid (Zyvox), vancomycin
- Volunteers
- 5,271 people
- Sponsor
- Pfizer
Skin Diseases, Infectious
Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections
The aim of this study is to see the efficacy and safety of BAY1192631 in Japanese patients with methicillin-resistant staphylococcus aureus (MRSA) (skin and soft tissue infections (SSTI) and SSTI-related bacteremia).
- Trial name
- NCT01967225
- Testing
- Tedizolid Phosphate (Sivextro, BAY1192631), Linezolid
- Where
- 46 sites in Japan
- Volunteers
- 125 people
- Sponsor
- Bayer
Drug Resistance, Microbial
Quinolone Resistance Profiles and Mechanisms of Staphylococcus Aureus and Escherichia Coli From Humans, Chicken and Catfish Farms in Indonesia
The goal of this observational study is to reveal quinolone resistance profiles and mechanisms in S. aureus and E. coli in the human, animal and aquaculture sector in Blitar, Indonesia.
- Trial name
- QUINDO (NCT05652556)
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Erasmus Medical Center
Cystic Fibrosis
STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)
To evaluate the micro-biologic efficacy and safety of a streamlined treatment for early onset methicillin-resistant staphylococcus aureus (MRSA) in patients with cystic fibrosis.
- Trial name
- STAR-TER (NCT03489629)
- Testing
- Trimethoprim Sulfamethoxazole (TMP/SMX), Minocycline, Mupirocin
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of North Carolina, Chapel Hill
Staphylococcus (S.) Aureus Infection
A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.
In this study, the candidate vaccine LTB-SA7 will be tested for safety and immunogenicity in healthy adults.
- Trial name
- LTBSA701 (NCT06719219)
- Testing
- LTB-SA7
- Where
- United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- LimmaTech Biologics AG
Staphylococcus Aureus Bacteremia
Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.
This study is a Phase I/II, double-blind, placebo-controlled trial investigating the True Human monoclonal antibody 514G3 in subjects hospitalized with Staphylococcus aureus bacteremia.
- Trial name
- NCT02357966
- Testing
- 514G3 (2 mg/kg) plus standard IV antibiotic treatment, 514G3 (10 mg/kg) plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- XBiotech, Inc.
Staphylococcal Infections
Bacterial Phenotype of Staphylococcus Aureus Has no Effect on Patients' Clinical Outcome in Orthopedic Device Related Bone Infections
This was a prospective study performed between November 2011 and September 2013. Patients with a confirmed S. aureus infection after fracture fixation or prosthetic joint infection were included.
- Trial name
- StaphType (NCT02971657)
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- BG Unfallklinik Murnau
Bacterial Resistance, Infection Resistant to Multiple Drugs
SATURN 04 Nosocomial Acquisition Study
The study is the WP4 of the EU-funded (7th FW) project SATURN (Impact of Specific Antibiotic Therapies on the prevalence of hUman host ResistaNt bacteria). A total of 6 surgical and 6 medical wards will participate in the study.
- Conditions
- Bacterial Resistance, Infection Resistant to Multiple Drugs, Staph Aureus Methicillin Resistant Colonization, Infection Due to ESBL Bacteria
- Trial name
- SATURN (NCT01208519)
- Where
- 3 sites in Italy, Romania and 1 more
- Volunteers
- 16,680 people
- Sponsor
- Catholic University of the Sacred Heart
Staphylococcal Infections
Vancomycin Study: Treatment of Catheter Related Bloodstream Infection Caused by Coagulase Negative Staphylococcus
Patients admitted into the Intensive Care Unit (ICU) have an intravenous (IV) catheter (small plastic tube) placed in their vein.
- Trial name
- NCT00175370
- Testing
- Vancomycin
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University of British Columbia
Staphylococcal Infections
Biofilm Formation in Staphylococcus Epidermidis Associated Implant Infections
This was a prospective study performed between November 2011 and September 2013. Patients with a confirmed S. epidermidis infection after fracture fixation or prosthetic joint infection were included.
- Trial name
- NCT02640937
- Where
- Germany
- Volunteers
- 124 people
- Sponsor
- BG Unfallklinik Murnau
Bacteremia Due to Methicillin Susceptible Staphylococcus Aureus
Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia
"Methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia remains a major cause of community- or hospital-acquired bloodstream infections with an overall mortality estimated around 25%.
- Trial name
- CLOCEBA (NCT03248063)
- Testing
- Cloxacillin, Cefazolin
- Where
- France
- Volunteers
- 315 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Surgical Site Infection, Staphylococcus Aureus Infection
Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®
DUOFAG® is a phage cocktail containing bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa. It is an investigational medicinal product for the treatment of surgical site infections caused by S.
- Conditions
- Surgical Site Infection, Staphylococcus Aureus Infection, Pseudomonas Aeruginosa Infection, Bacterial Infections
- Trial name
- NCT06319235
- Testing
- IMP
- Where
- Czechia
- Volunteers
- 52 people
- Sponsor
- MB PHARMA s.r.o.
Abscess Soft Tissue, Methicillin-resistant Staphylococcus Aureus (MRSA) Infection
Randomized Controlled Trial of Antibiotics in the Management of Children With Community-Acquired Abscess
The purpose of this study is to better understand why children develop methicillin-resistant Staphylococcus aureus (MRSA) skin infections that require surgical drainage and whether antibiotics are helpful after the infection is…
- Conditions
- Abscess Soft Tissue, Methicillin-resistant Staphylococcus Aureus (MRSA) Infection, Skin Abscess
- Trial name
- NCT01498744
- Testing
- Oral Clindamycin
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago